A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)
Not Applicable
- Conditions
- -Z21 Asymptomatic human immunodeficiency virus [HIV] infection statusAsymptomatic human immunodeficiency virus [HIV] infection statusZ21
- Registration Number
- PER-092-06
- Lead Sponsor
- MERCK SHARP & DOHME PERU S.R.L.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
1) Participant is a male or female at least 18 years of age.
2) Participant is HIV positive.
3) Participant is naive to antiretroviral therapy (ART) and has not received any ART.
Exclusion Criteria
1) Participant has received approved or experimental antiretroviral agents in the past.
2) Participant has been treated for a viral infection other than HIV.
3) Participant has documented resistance to tenofovir, emtricitabine, and/or efavirenz.
4) Participant has used another experimental HIV-integrase inhibitor.
5) Participant has a current (active) diagnosis of acute hepatitis.
6) Participants with chronic hepatitis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method